Company Directory - Indivior
Company Details - Indivior
Indivior
WebsiteIndivior is a global pharmaceutical company focused on the development and commercialization of innovative medicines for the treatment of addiction and related disorders, including opioid dependence. The company's mission is to help people achieve recovery through effective treatments and support services.
CCI Score
CCI Score: Indivior
-27.68
Latest Event
Final $600M Opioid Settlement and Corporate Restructuring
Indivior has reached a final $600M settlement over opioid litigation stemming from allegations of engaging in an illicit nationwide scheme to boost prescriptions of its opioid addiction treatment, Suboxone Film. The settlement, which also mandates structural changes such as disbanding its Suboxone sales force and removing high-risk promoters, represents a legal and regulatory repercussion for the company's unethical marketing practices.
Take Action
So what can you do? It's time to make tough choices. Where will you cast your vote?
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
ACCOMPLICE
Indivior is currently rated as an Accomplice.
Latest Events
- MAY302025
Indivior has reached a final $600M settlement over opioid litigation stemming from allegations of engaging in an illicit nationwide scheme to boost prescriptions of its opioid addiction treatment, Suboxone Film. The settlement, which also mandates structural changes such as disbanding its Suboxone sales force and removing high-risk promoters, represents a legal and regulatory repercussion for the company's unethical marketing practices.
-50
Business Practices and Ethical Responsibility
June 2
The settlement highlights Indivior's unethical business practices and misleading promotional strategies tied to its opioid products. By engaging in an illicit scheme that exaggerated product safety claims and promoted prescriptions irresponsibly, the company undermined ethical standards and public trust, necessitating heavy legal consequences. This award of negative points reflects the company’s role in practices that can contribute to broader societal harm.
After final $600M opioid settlement, Indivior looks to the future
- OCT012023
Indivior's website outlines its principles for third-party business partners, emphasizing ethical standards in supply chain management including human rights, labor practices, health & safety, and environmental measures.
+50
Supply Chain Ethics
June 2
Indivior has publicly disclosed the ethical expectations it holds for its third-party business partners regarding supply chain practices. This transparency and commitment to upholding labor rights, human rights, and environmental standards align with anti-fascist and progressive values by promoting corporate accountability and ethical business practices.
- JUN022023
Indivior reached a $102.5 million settlement with New York Attorney General Letitia James and 41 other state attorneys general over allegations of monopolistic practices that suppressed generic competition for its opioid addiction treatment drug, Suboxone. The settlement requires Indivior to disclose its FDA Citizen Petitions and notify states of new products or changes in corporate control to prevent recurrence of anticompetitive behavior.
-80
Business Practices and Ethical Responsibility
June 2
Indivior engaged in clearly unethical business practices by deliberately manipulating its product portfolio to suppress generic competition and maintain a market monopoly. These actions harmed patients by limiting access to more affordable medication, exacerbating issues related to the opioid crisis.
-65
Economic and Structural Influence
June 2
By using a series of anticompetitive strategies, including leveraging regulatory submissions and altering product forms, Indivior structured the market in its favor at the expense of generic competitors and economic fairness. This conduct undermines healthy market competition and concentrates economic power.
- JUL242020
Indivior Solutions pleaded guilty to a felony charge for making false statements in the marketing of Suboxone Film, and along with its parent companies, agreed to a $600 million settlement to resolve criminal and civil liabilities relating to unethical promotion practices during the opioid crisis.
-70
Business Practices and Ethical Responsibility
June 2
The event reveals that Indivior engaged in unethical business practices by deliberately misleading healthcare officials through false promotional data about Suboxone Film, contributing to the broader opioid crisis. Such actions undermine public trust and place profits above public safety, which is detrimental to vulnerable communities.
Indivior Solutions Pleads Guilty to Felony Charge and Indivior Entities Agree to Pay $600 Million
Alternatives
Thousand Oaks, USA
13.45
Foster City, USA
1.62
Corporation
17.00
Corporation
0.00
Corporation
0.00
Corporation
0.00
Belgium (Ghent), Belgium
78.10
Raleigh, USA
55.85
Bagsværd, Denmark
18.59
Houston, United States
13.36
Corporate Financials
- Revenue
- 2023
- $700.00M
- Operating Income
- 2023
- $60.00M
Industries
- 325412
- Pharmaceutical Preparation Manufacturing
- 541714
- Research and Development in Biotechnology (except Nanobiotechnology)
- 621511
- Medical Laboratories